Company intelligence / Profile preview
Guangzhou FineImmune Biotechnology
Guangzhou, Guangdong Sheng / Guangdong Province, Chinafineimmu.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
FineImmune has developed the first personalized neoantigen-specific TCR-T cell therapy currently in Phase I clinical trial. Multiple other immune cell therapies are also in early-stage clinical development. The company claims to have solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies enabling precision prediction of efficacy and side effects of immunotherapies. Over twenty immune cell therapy products and technologies are under R&D.[5][6]
- Therapeutic areas
- OncologyNephrology
- Modalities
- TCR-T cell therapy (T-cell receptor engineered T cells)CAR-T cell therapy (Chimeric Antigen Receptor T cells)TAL (T-cell Antigen Lymphocytes)TIL (Tumor-Infiltrating Lymphocytes)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Biocytogen Pharmaceuticals — strategic collaboration to co-develop antibody-based/cell therapies targeting intracellular tumor-associated antigens using Biocytogen’s proprietary platforms combined with FineImmune’s technology.[5][6][9][10]
Beyond the preview
Go deeper on Guangzhou FineImmune Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou FineImmune Biotechnology.